RU2004126862A - Соли валсартана - Google Patents

Соли валсартана Download PDF

Info

Publication number
RU2004126862A
RU2004126862A RU2004126862/04A RU2004126862A RU2004126862A RU 2004126862 A RU2004126862 A RU 2004126862A RU 2004126862/04 A RU2004126862/04 A RU 2004126862/04A RU 2004126862 A RU2004126862 A RU 2004126862A RU 2004126862 A RU2004126862 A RU 2004126862A
Authority
RU
Russia
Prior art keywords
salt
valsartan
pharmaceutically acceptable
guinier
powder
Prior art date
Application number
RU2004126862/04A
Other languages
English (en)
Russian (ru)
Inventor
МАРТИ Эрвин (CH)
Марти Эрвин
Original Assignee
Новартис АГ (CH)
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис АГ (CH), Новартис Аг filed Critical Новартис АГ (CH)
Publication of RU2004126862A publication Critical patent/RU2004126862A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
RU2004126862/04A 2002-02-04 2003-02-03 Соли валсартана RU2004126862A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35419902P 2002-02-04 2002-02-04
US60/354,199 2002-02-04

Publications (1)

Publication Number Publication Date
RU2004126862A true RU2004126862A (ru) 2005-06-27

Family

ID=27734333

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004126862/04A RU2004126862A (ru) 2002-02-04 2003-02-03 Соли валсартана

Country Status (17)

Country Link
US (3) US6869970B2 (cg-RX-API-DMAC7.html)
EP (1) EP1474402A1 (cg-RX-API-DMAC7.html)
JP (2) JP4895475B2 (cg-RX-API-DMAC7.html)
KR (3) KR20040081178A (cg-RX-API-DMAC7.html)
CN (2) CN100548993C (cg-RX-API-DMAC7.html)
AU (1) AU2003214054B2 (cg-RX-API-DMAC7.html)
BR (1) BR0307442A (cg-RX-API-DMAC7.html)
CA (2) CA2776902A1 (cg-RX-API-DMAC7.html)
CO (1) CO5611107A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP045221A (cg-RX-API-DMAC7.html)
MX (1) MXPA04007525A (cg-RX-API-DMAC7.html)
NO (1) NO328155B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ534560A (cg-RX-API-DMAC7.html)
PL (1) PL370481A1 (cg-RX-API-DMAC7.html)
RU (1) RU2004126862A (cg-RX-API-DMAC7.html)
WO (1) WO2003066606A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200405698B (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
US6869970B2 (en) 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
ES2315510T3 (es) * 2002-06-13 2009-04-01 Novartis Ag Sales de calcio de estatinas derivadas del indol.
DE602004013405T2 (de) * 2003-03-17 2009-05-07 Teva Pharmaceutical Industries Ltd. Polymorphe formen von valsartan
MXPA05012299A (es) * 2003-05-16 2006-01-30 Novartis Ag Composicion farmaceutica que comprende valsartan.
CA2544747A1 (en) * 2003-11-14 2005-05-26 Novartis Ag At1-receptor antagonists for treating nephrotic syndrome
WO2005049587A1 (en) * 2003-11-21 2005-06-02 Ranbaxy Laboratories Limited Process for preparation of biphenyl tetrazole
ITMI20032267A1 (it) * 2003-11-21 2005-05-22 Dinamite Dipharma S P A In Forma A Bbreviata Diph Procdimento per la preparzione di valsartan e suoi intermedi
TWI328006B (en) * 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
ES2277199T3 (es) * 2004-04-15 2007-07-01 Helm Ag Procedimiento para la preparacion de adsorbatos de valsartan pulverulentos de flujo libre.
PE20060416A1 (es) * 2004-08-03 2006-06-09 Novartis Ag Composicion de inhibidores de renina e inhibidores de proteinas de efusion
WO2006021443A2 (en) * 2004-08-26 2006-03-02 Novartis Ag Composition comprising an at1 receptor blocker and a macrolide t-cell immunomodulator
EP1806137A4 (en) * 2004-10-29 2011-03-30 Kowa Co THERAPEUTIC AGENT FOR THE TREATMENT OF GLOMERULAR DISEASE
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
AR057882A1 (es) * 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
US20090304797A1 (en) * 2006-06-23 2009-12-10 Tarur Venkatasubramanian Radha Process for the Preparation of Micronized Valsartan
PE20120542A1 (es) 2006-06-27 2012-05-14 Novartis Ag Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas
WO2008018843A1 (en) * 2006-08-08 2008-02-14 Ulkar Kimya Sanayi Ve Ticaret As Process for producing useful salts form of biphenyl-tetrazole compounds
PE20080907A1 (es) * 2006-08-31 2008-08-22 Novartis Ag Sistema de suministro de farmaco oral gastro-retentivo de liberacion extendida para valsartan
WO2008088727A2 (en) 2007-01-12 2008-07-24 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US8080549B2 (en) * 2007-01-12 2011-12-20 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
CN101396366B (zh) * 2007-09-25 2010-10-13 浙江华海药业股份有限公司 含缬沙坦的固体口服制剂及其制备方法
ES2336755B1 (es) * 2008-10-07 2011-01-21 Activery Biotech, S.L. Procedimiento para la preparacion de combinaciones de valsartan y simvastatina.
JP2011063518A (ja) * 2009-09-15 2011-03-31 Tohoku Univ Arb及び/又はグリタゾン系血糖降下物質を含有するoatp−r遺伝子発現増強組成物
WO2012016969A1 (en) 2010-08-03 2012-02-09 Novartis Ag Highly crystalline valsartan
CN103012301B (zh) * 2013-01-05 2015-06-17 江苏施美康药业股份有限公司 缬沙坦甲酯碱金属盐及其制备方法
DE102014004512A1 (de) * 2014-03-28 2015-10-01 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Bereich Universitätsmedizin Anorganisch-organische Hybridverbindung
WO2017012600A1 (en) 2015-07-20 2017-01-26 Zentiva, K.S. A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
EP3498698A1 (en) 2017-12-15 2019-06-19 Mankind Pharma Ltd Solid forms of valsartan disodium and process of preparation thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0443983B1 (de) * 1990-02-19 1996-02-28 Ciba-Geigy Ag Acylverbindungen
KR19980703647A (ko) * 1995-04-07 1998-12-05 베르너발데크 베나제프릴 또는 베나제프릴라트 및 발사르탄을 함유하는조성물
ES2099031B1 (es) 1995-05-31 1997-12-01 Esteve Labor Dr Nuevos polimorfos de diclorhidrato de lesopitron y sus formas hidratadas, procedimientos de preparacion y composiciones que los contienen.
US5877193A (en) * 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
EP0968434A2 (en) * 1997-02-28 2000-01-05 Burstein Laboratories, Inc. Laboratory in a disk
US6641886B1 (en) * 1999-03-23 2003-11-04 Flexplay Technologies, Inc. Directory read inhibitor for optical storage media
JP2001155346A (ja) * 1999-11-26 2001-06-08 Toshiba Corp 情報記録媒体、情報記録装置、情報記録方法、情報再生装置、情報再生方法
IL152411A0 (en) 2000-04-24 2003-05-29 Teva Pharma Zolpidem hemitartrate
US20020132839A1 (en) * 2000-06-22 2002-09-19 Ganter Sabina Maria Tablet formulations comprising valsartan
CZ303389B6 (cs) 2000-07-19 2012-08-29 Novartis Ag Sul valsartanu a farmaceutický prípravek obsahující tuto sul
US6869970B2 (en) 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan

Also Published As

Publication number Publication date
WO2003066606A1 (en) 2003-08-14
CA2776902A1 (en) 2003-08-14
US20030171414A1 (en) 2003-09-11
CN100548993C (zh) 2009-10-14
PL370481A1 (en) 2005-05-30
CN101633646B (zh) 2012-08-29
KR20040081178A (ko) 2004-09-20
US20050101652A1 (en) 2005-05-12
US6869970B2 (en) 2005-03-22
NO20043660L (no) 2004-10-12
JP2005517696A (ja) 2005-06-16
CA2474424C (en) 2013-03-26
AU2003214054B2 (en) 2007-08-16
AU2003214054A1 (en) 2003-09-02
MXPA04007525A (es) 2004-11-10
US8058301B2 (en) 2011-11-15
HK1139681A1 (en) 2010-09-24
KR20110101257A (ko) 2011-09-15
CO5611107A2 (es) 2006-02-28
CA2474424A1 (en) 2003-08-14
JP5303370B2 (ja) 2013-10-02
US8329919B2 (en) 2012-12-11
JP4895475B2 (ja) 2012-03-14
NO328155B1 (no) 2009-12-21
KR20120054667A (ko) 2012-05-30
CN101633646A (zh) 2010-01-27
EP1474402A1 (en) 2004-11-10
NZ534560A (en) 2007-05-31
ZA200405698B (en) 2006-05-31
BR0307442A (pt) 2005-01-04
JP2009235086A (ja) 2009-10-15
CN1628106A (zh) 2005-06-15
US20120022268A1 (en) 2012-01-26
ECSP045221A (es) 2004-09-28

Similar Documents

Publication Publication Date Title
JP2009235086A5 (cg-RX-API-DMAC7.html)
RU2003104789A (ru) Соли валсартана
CA2415962A1 (en) Valsartan salts
JP2005517696A5 (cg-RX-API-DMAC7.html)
RU2008141373A (ru) Соль алискирена и серной кислоты
Kawasaki et al. Crystal growth and disequilibrium distribution of oxygen isotopes in an igneous Ca-Al-rich inclusion from the Allende carbonaceous chondrite
CA2474424C (en) Salts of valsartan
RU2011127679A (ru) Высокоактивные молекулярные сита со структурой типа мтт
CA2410234C (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis
CA2682859A1 (en) Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl)indazole for treatment of abnormal cell growth in mammals
JP2009517023A5 (cg-RX-API-DMAC7.html)
KR100975782B1 (ko) 플루바스타틴 나트륨의 결정 형태
Okada et al. Effects of grinding and firing conditions on CaAl2Si2O8 phase formation by solid-state reaction of kaolinite with CaCO3
Xia et al. Studies on the basic compounds of magnesia cement: the thermal behaviour of magnesium oxychlorides
NZ507914A (en) Polymorphic clopidogrel hydrogenesulphate form
RU2007144531A (ru) Новые кристаллические формы тиотропийбромида
ZA200807025B (en) Beta-crystalline form of perindopril arginine salt, method for making same, and pharmaceutical compositions containing same
AR034124A1 (es) Forma cristalina alfa de la sal de terbutilamina de perindopril, procedimiento para su preparacion y composiciones farmaceuticas que la contienen
AU2001264804A1 (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis
HUT53078A (en) Process for producing piperidine derivatives
JP2003514859A5 (cg-RX-API-DMAC7.html)
CA2391650A1 (en) Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl
CA2447878C (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis
SK287644B6 (sk) Kryštalický N-(trans)-4-izopropylcyklohexylkarbonyl)-D- fenylalanín vo forme C a spôsob jeho prípravy
PT922048E (pt) Processo para a preparacao de n-¬(1-"butil-4-piperidinil)metil|-3,4-di-hidro-2h-¬1,3|oxazino¬3,2-a|indolo-10-carboxamida seus sais e compostos intermedios do processo